Skip to content

HeAlth-data Register sTudies of Risk and Outcomes in Cardiac Surgery

HeAlth-data Register sTudies of Risk and Outcomes in Cardiac Surgery (HARTROCS)

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT02276950
Acronym
HARTROCS
Enrollment
150000
Registered
2014-10-28
Start date
2011-01-31
Completion date
2027-12-31
Last updated
2024-10-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cardiovascular Diseases, Depression, Diabetes Mellitus, Kidney Diseases

Keywords

Cardiac Surgery, Epidemiologic Methods, Blood Transfusions

Brief summary

The overall project aim is to study risk and outcomes following cardiac surgery by cross-linking high-quality national Swedish health-data registers for population-based investigations of individual level clinically relevant patient data.

Detailed description

The purpose of this research project is to study risks and outcomes in patients who underwent cardiac surgery. We aim to establish a fundament for the conduct of nationwide population-based studies by linking patient-level data from the Swedish Heart Surgery Register (SWEDEHEART), the National Patient Register, the Cause of Death Register, the National Diabetes Register, the Swedish Renal Registry, the Prescribed Drug Register, and the 2nd version of the Swedish-Danish Scandinavian Donations and Transfusions database. Cross-linking patient-level data is possible through the Personal Identity Number assigned to every individual who has resided in Sweden on a permanent basis. The Swedish Personal Identity Number is the unique identifier in all national registers. Specifically, we aim: 1. To assess the importance of chronic kidney disease for prognosis after CABG. 2. To assess the consequences of acute kidney injury following CABG. 3. To analyze the prognosis in patients with depression prior to CABG. 4. To study risks and benefits of blood transfusions in cardiac surgery. 5. To study the risks associated with diabetes mellitus in cardiac surgery with special reference to type of diabetes (type 1 and type 2) and glycaemic control and duration of disease. 6. To investigate the long-term impact of different surgical strategies (e.g. use of multiple arterial grafts or non-use of cardio-pulmonary bypass) during CABG. 7. To analyze prognosis in relevant sub-populations undergoing CABG (e.g. patients 50 years or younger, possible differences between men and women, and patients with heart failure with preserved vs. reduced ejection fraction). 8. To investigate survival and morbidity in patients between 50 and 69 years undergoing aortic valve replacement with particular reference to prosthesis type (mechanical vs. biological). 9. To analyze the association between socioeconomic factors and prognosis in patients undergoing cardiac surgery. 10. To investigate factors related to durability of bioprosthetic aortic heart valves.

Interventions

PROCEDURECoronary artery bypass surgery

Primary isolated coronary artery bypass surgery with or without use of cardio-pulmonary bypass

Heart valve surgery, aortic valve replacement or other heart valve procedures

Sponsors

Karolinska Institutet
CollaboratorOTHER
Ulrik Sartipy, MD, PhD
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

All adult patients who underwent cardiac surgery in Sweden during the study period

Exclusion criteria

\-

Design outcomes

Primary

MeasureTime frame
All-cause mortality15 years

Secondary

MeasureTime frameDescription
Heart Failure15 years
Stroke15 years
End-Stage Renal Disease15 years
Myocardial Infarction15 years
Cardiovascular Death15 years
Aortic valve reoperation15 years
Composite15 yearsCombined end-point of death and other secondary end-points
Repeat Revascularization15 years

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 15, 2026